Key result
Nasal immunization of female mice with rotavirus virus-like particles containing VP7 (VLP2/6/7) significantly protected their suckling pups against rotavirus-induced diarrhea, reducing incidence to 27% compared to 93.7% in controls.
Why the study?
Does nasal immunization of female mice with rotavirus VLPs protect their offspring against rotavirus diarrhea?
Does nasal immunization of female mice with rotavirus VLPs protect their offspring against rotavirus diarrhea?
Absolute Event Rate: 27% vs 93.7%
p-value: p=<0.05
Nasal immunization of mothers with VP7-containing rotavirus VLPs is a promising strategy to protect suckling newborns against rotavirus diarrhea via milk antibodies.
Caution against clinical use from mouse data alone; leaves open human translation of maternal nasal rotavirus VLP immunization.
Rotavirus is the major cause of diarrhea among young infants in both humans and animals. Immune protection of newborns by vaccination is difficult to achieve since there is not enough time to mount an immune response before exposure to the virus. We have designed a vaccination strategy mediating transfer of neutralizing antibodies from the mother to the offspring during pregnancy and/or lactation. Adult female mice were nasally immunized with virus-like particles (VLPs) made of viral proteins VP2 and 6 (VLP2/6) or VP 2, 6, and 7 (VLP2/6/7) derived from the RF rotavirus strain in the presence or absence of cholera toxin. Both vaccines elicited serum and milk antibodies against the respective VPs. Four days after parturition, suckling pups were challenged orally with RF rotavirus. Pups from mothers immunized with VLP2/6/7 but not VLP2/6 were protected against rotavirus diarrhea, indicating that VP7 plays a key role in protection. Protection was mediated by milk rather than serum antibodies, and mucosal adjuvants were not required. In conclusion, VLPs containing VP7 administered nasally to mothers represent a promising vaccine candidate for the protection of suckling newborns against rotavirus-induced diarrhea, even in the absence of a mucosal adjuvant.
No takes yet. Share an insight, caveat, or question.
Coste et al. (2000) studied Rotavirus diarrhea. VLP2/6/7 (virus-like particles containing VP2, VP6, and VP7) vs. PBS, CT alone, or VLP2/6 was evaluated on Incidence of diarrhea in pups following oral rotavirus challenge (p=<0.05). Nasal immunization of female mice with rotavirus virus-like particles containing VP7 (VLP2/6/7) significantly protected their suckling pups against rotavirus-induced diarrhea, reducing incidence to 27% compared to 93.7% in controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: